The innovative company Thermosome announced that in April 2023 it launched a phase I clinical trial called „TH001”, in which patients suffering from locally advanced soft tissue sarcoma (often referred to as „STS”) are tested on the so-called thermosomes, i.e. innovative lipid microcapsules that release the cytostatic drug contained in them (in this case Doxorubicin) only under the influence of increased local temperature.
In the treatment of these often inoperable tumors, this method may turn out to be a breakthrough: thermosome technology allows to achieve 15 times higher drug concentration in the tumor area compared to other tissues.
The results of the preclinical studies are extremely promising, which is why the TH001 study received funding from an EMA grant for rare diseases.
More details can be found HERE.
Belgradzka street 5
+48 22 300 91 85
Monday - Friday from 8:00 to 18:00